Combination therapy with DNA-damaging agents

The intravenous PARPi PF-1367338 has been investigated in the clinic for several years, and recently a Phase II study coupling PF-1367338 with cisplatin was initiated in TNBC patients [46]. A Phase II study with 

Combination studies of olaparib are being explored clinically with a number of agents, including irinotecan, dacarbazine, carboplatin, gemcitabine, doxorubicin, cisplatin, and topotecan. 

APPLICATION TO TUMORS WITH OTHER DNA DAMAGE REPAIR DEFICIENCIES 

TANKYRASE INHIBITION AS A STRATEGY FOR Wnt/p-CATENIN PATHWAY MODULATION 

The second group identified 41, which inhibited Wnt pathway activity and proliferation of cancer cells with an aberrant Wnt pathway at micromolar concentrations in contrast, the structurally related analog 42 had no effect. Immobilization of 41 and affinity capture followed by proteo-mics identified several potential targets, including TANK-1 and TANK-2, 

---